Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections Jun 29, 2020
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Jun 3, 2020
Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection Jun 1, 2020
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI) Mar 31, 2020
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference Feb 19, 2020
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors Jan 17, 2020
